Takeda's Rozerem Substance Abuse/Toxicity Claims Draw FDA Rebuke

Takeda misrepresents its sleep aid Rozerem (ramelteon) in sales materials aimed at physicians who treat substance abusers by claiming the product has "no likelihood of abuse and no detectable toxicity," FDA's Division of Drug Marketing, Advertising and Communications charges